Celeste D. Bickford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Celeste D. Bickford has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Gillian Elizabeth Hanley
Department of Gynaecology and Obstetrics, Division of Gynaecologic Oncology, University of British Columbia, Vancouver, BC, Canada
2 shared publications - Timothy F. Oberlander
University of British Columbia
2 shared publications - Anne Synnes
Division of Neonatology, BC Children’s Hospital Research Institute, BC Women’s Hospital, Vancouver, Canada
1 shared publication - Bruce Perrin Lanphear
Faculty of Health Sciences, Simon Fraser University, Vancouver, Canada
1 shared publication - Craig Mitton
Prioritize Consulting, The University of British Columbia, Vancouver, Canada
1 shared publication - Diane Sawchuck
Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of British Columbia, Vancouver, Canada
1 shared publication
Latest Publications
- Open Access
- 30 July 2022
- Published by Elsevier in Environment International
- Vol. 167, 107445
The association between prenatal greenspace exposure and Autism spectrum disorder, and the potentially mediating role of air pollution reduction: A population-based birth cohort study
- 30 July 2022
- Published by Elsevier in Environment International
- Vol. 167, 107445
Open AccessThe association between prenatal greenspace exposure and Autism spectrum disorder, and the potentially mediating role of air pollution reduction: A population-based birth cohort study
- 4 December 2019
- Published by Wiley in Autism Research
- Vol. 13 (3) , 456-463
Identification of Pediatric Autism Spectrum Disorder Cases Using Health Administrative Data
Administrative data are frequently used to identify Autism Spectrum Disorder (ASD) cases in epidemiological studies. However, validation studies on this mode of case ascertainment have lacked access to high‐quality clinical diagnostic data and have not followed published reporting guidelines. We report on the diagnostic accuracy of using readily available health administrative data for pediatric ASD case ascertainment. The validation cohort included almost all the ASD‐positive children born in British Columbia, Canada from April 1, 2000 to December 31, 2009 and consisted of 8,670 children in total. 4,079 ASD‐positive and 2,787 ASD‐negative children were identified using Autism Diagnostic Observation Schedule (ADOS) and Autism Diagnostic Interview‐Revised (ADI‐R) assessments done through the British Columbia Autism Assessment Network (BCAAN). An additional 1,804 ADOS/ADI‐R assessed ASD‐positive children were identified using Ministry of Education records. This prospectively collected clinical data (the diagnostic gold standard) was then linked to each child's physician billing and hospital discharge data. The diagnostic accuracy of 11 algorithms that used the administrative data to assign ASD case status was assessed. For all algorithms, high positive predictive values (PPVs) were observed alongside low values for other measures of diagnostic accuracy illustrating that PPVs alone are not an adequate measure of diagnostic accuracy. We show that British Columbia's health administrative data cannot reliably be used to discriminate between children with ASD and children with other developmental disorders. Utilizing these data may result in misclassification bias. Methodologically sound, region‐specific validation studies are needed to support the use of administrative data for ASD case ascertainment. Autism Res 2020, 13: 456–463. © 2019 International Society for Autism Research, Wiley Periodicals, Inc.Lay Summary: Health administrative data are frequently used to identify Autism Spectrum Disorder (ASD) cases for research purposes. However, previous validation studies on this sort of case identification have lacked access to high‐quality clinical diagnostic data and have not followed published reporting guidelines. We show that British Columbia's health administrative data cannot reliably be used to discriminate between children with ASD and children with other developmental disorders.
- 4 December 2019
- Published by Wiley in Autism Research
- Vol. 13 (3) , 456-463
Identification of Pediatric Autism Spectrum Disorder Cases Using Health Administrative Data
Administrative data are frequently used to identify Autism Spectrum Disorder (ASD) cases in epidemiological studies. However, validation studies on this mode of case ascertainment have lacked access to high‐quality clinical diagnostic data and have not followed published reporting guidelines. We report on the diagnostic accuracy of using readily available health administrative data for pediatric ASD case ascertainment. The validation cohort included almost all the ASD‐positive children born in British Columbia, Canada from April 1, 2000 to December 31, 2009 and consisted of 8,670 children in total. 4,079 ASD‐positive and 2,787 ASD‐negative children were identified using Autism Diagnostic Observation Schedule (ADOS) and Autism Diagnostic Interview‐Revised (ADI‐R) assessments done through the British Columbia Autism Assessment Network (BCAAN). An additional 1,804 ADOS/ADI‐R assessed ASD‐positive children were identified using Ministry of Education records. This prospectively collected clinical data (the diagnostic gold standard) was then linked to each child's physician billing and hospital discharge data. The diagnostic accuracy of 11 algorithms that used the administrative data to assign ASD case status was assessed. For all algorithms, high positive predictive values (PPVs) were observed alongside low values for other measures of diagnostic accuracy illustrating that PPVs alone are not an adequate measure of diagnostic accuracy. We show that British Columbia's health administrative data cannot reliably be used to discriminate between children with ASD and children with other developmental disorders. Utilizing these data may result in misclassification bias. Methodologically sound, region‐specific validation studies are needed to support the use of administrative data for ASD case ascertainment. Autism Res 2020, 13: 456–463. © 2019 International Society for Autism Research, Wiley Periodicals, Inc.Lay Summary: Health administrative data are frequently used to identify Autism Spectrum Disorder (ASD) cases for research purposes. However, previous validation studies on this sort of case identification have lacked access to high‐quality clinical diagnostic data and have not followed published reporting guidelines. We show that British Columbia's health administrative data cannot reliably be used to discriminate between children with ASD and children with other developmental disorders.
- Open Access
- 19 December 2013
- Published by Springer Nature in BMC Health Services Research
- Vol. 13 (1) , 1-12
Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
The aim of this study was to assess the cost-effectiveness of administering magnesium sulphate to patients in whom preterm birth at < 32+0 weeks gestation is either imminent or threatened for the purpose of fetal neuroprotection. Multiple decision tree models and probabilistic sensitivity analyses were used to compare the administration of magnesium sulphate with the alternative of no treatment. Two separate cost perspectives were utilized in this series of analyses: a health system and a societal perspective. In addition, two separate measures of effectiveness were utilized: cases of cerebral palsy (CP) averted and quality-adjusted life years (QALYs). From a health system and a societal perspective, respectively, a savings of $2,242 and $112,602 is obtained for each QALY gained and a savings of $30,942 and $1,554,198 is obtained for each case of CP averted when magnesium sulphate is administered to patients in whom preterm birth is imminent. From a health system perspective and a societal perspective, respectively, a cost of $2,083 is incurred and a savings of $108,277 is obtained for each QALY gained and a cost of $28,755 is incurred and a savings of $1,494,500 is obtained for each case of CP averted when magnesium sulphate is administered to patients in whom preterm birth is threatened. Administration of magnesium sulphate to patients in whom preterm birth is imminent is a dominant (i.e. cost-effective) strategy, no matter what cost perspective or measure of effectiveness is used. Administration of magnesium sulphate to patients in whom preterm birth is threatened is a dominant strategy from a societal perspective and is very likely to be cost-effective from a health system perspective.
- 19 December 2013
- Published by Springer Nature in BMC Health Services Research
- Vol. 13 (1) , 1-12
Open AccessMagnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
The aim of this study was to assess the cost-effectiveness of administering magnesium sulphate to patients in whom preterm birth at < 32+0 weeks gestation is either imminent or threatened for the purpose of fetal neuroprotection. Multiple decision tree models and probabilistic sensitivity analyses were used to compare the administration of magnesium sulphate with the alternative of no treatment. Two separate cost perspectives were utilized in this series of analyses: a health system and a societal perspective. In addition, two separate measures of effectiveness were utilized: cases of cerebral palsy (CP) averted and quality-adjusted life years (QALYs). From a health system and a societal perspective, respectively, a savings of $2,242 and $112,602 is obtained for each QALY gained and a savings of $30,942 and $1,554,198 is obtained for each case of CP averted when magnesium sulphate is administered to patients in whom preterm birth is imminent. From a health system perspective and a societal perspective, respectively, a cost of $2,083 is incurred and a savings of $108,277 is obtained for each QALY gained and a cost of $28,755 is incurred and a savings of $1,494,500 is obtained for each case of CP averted when magnesium sulphate is administered to patients in whom preterm birth is threatened. Administration of magnesium sulphate to patients in whom preterm birth is imminent is a dominant (i.e. cost-effective) strategy, no matter what cost perspective or measure of effectiveness is used. Administration of magnesium sulphate to patients in whom preterm birth is threatened is a dominant strategy from a societal perspective and is very likely to be cost-effective from a health system perspective.